Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berk-Planken, I. I.L.
Right arrow Articles by Jansen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berk-Planken, I. I.L.
Right arrow Articles by Jansen, H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 26:427-432, 2003
© 2003 by the American Diabetes Association, Inc.

Emerging Treatments and Technologies
Original Article

Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes

Effect of sex and the LIPC promoter variant

Ingrid I.L. Berk-Planken, MD1, Nicoline Hoogerbrugge, MD, PHD1,2, Ronald P. Stolk, MD, PHD3, Aart H. Bootsma, MD, PHD1 and Hans Jansen, MRBC, PHD1,4 on behalf of the DALI study group

1 Department of Internal Medicine, Erasmus MC, Erasmus University Rotterdam, Rotterdam, the Netherlands
2 Department of Human Genetics, University Medical Center Nijmegen, Nijmegen, the Netherlands
3 Julius Center for Patient Oriented Research, Utrecht, the Netherlands
4 Departments of Biochemistry and Clinical Chemistry, Erasmus MC, Erasmus University Rotterdam, Rotterdam, the Netherlands

OBJECTIVE—Hepatic lipase (HL) is involved in the metabolism of several lipoproteins and may contribute to the atherogenic lipid profile in type 2 diabetes. Little is known about the effect of cholesterol synthesis inhibitors on HL activity in relation to sex and the hepatic lipase gene, the LIPC promoter variant in type 2 diabetes. Therefore, we studied the effect of atorvastatin 10 mg (A10) and 80 mg (A80) on HL activity in 198 patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—Patients (aged 45–75 years, without manifest coronary artery disease, total cholesterol 4.0–8.0 mmol/l, and fasting triglycerides [TG] 1.5–6.0 mmol/l) were included in a double-blind, randomized, placebo-controlled trial for 30 weeks (Diabetes Atorvastatin Lipid Intervention study).

RESULTS—HL activity at baseline was significantly higher in our population compared with an age-matched control group without type 2 diabetes (406 ± 150 vs. 357 ± 118 units/l). HL activity in men versus women (443 ± 158 vs. 358 ± 127 units/l), in carriers of the LIPC C/C allele versus carriers of the T/T allele (444 ± 142 vs. 227 ± 96 units/l), and in Caucasians versus blacks (415 ± 150 vs. 260 ± 127 units/l) all differed significantly (P < 0.001). Atorvastatin dose-dependently decreased HL (A10, -11%; A80, -22%; both P < 0.001). Neither sex nor the LIPC C->T variation influenced the effect of atorvastatin on HL activity.

CONCLUSIONS—Sex, LIPC promoter variant, and ethnicity significantly contribute to the baseline variance in HL activity. Atorvastatin treatment in diabetic dyslipidemia results in a significant dose-dependent decrease in HL activity, regardless of sex or the LIPC promoter variant.

Abbreviations: CAD, coronary artery disease • DALI, Diabetes Atorvastatin Lipid Intervention • FFA, free fatty acid • HL, hepatic lipase • TG, triglycerides • WHR, waist-to-hip ratio


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
G. Bos, J. M Dekker, E. J. Feskens, M. C Ocke, G. Nijpels, C. D. Stehouwer, L. M Bouter, R. J Heine, and H. Jansen
Interactions of dietary fat intake and the hepatic lipase -480C->T polymorphism in determining hepatic lipase activity: the Hoorn Study
Am. J. Clinical Nutrition, April 1, 2005; 81(4): 911 - 915.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Treguier, C. Doucet, M. Moreau, C. Dachet, J. Thillet, M. J. Chapman, and T. Huby
Transcription Factor Sterol Regulatory Element Binding Protein 2 Regulates Scavenger Receptor Cla-1 Gene Expression
Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2358 - 2364.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Isaacs, F. A. Sayed-Tabatabaei, O. T. Njajou, J. C. M. Witteman, and C. M. van Duijn
The -514 C->T Hepatic Lipase Promoter Region Polymorphism and Plasma Lipids: A Meta-Analysis
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3858 - 3863.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. C. Sposito, S. Gonbert, E. Bruckert, M. Atassi, I. Beucler, S. Amsellem, O. Khallouf, P. Benlian, and G. Turpin
Magnitude of HDL Cholesterol Variation After High-Dose Atorvastatin Is Genetically Determined at the LDL Receptor Locus in Patients With Homozygous Familial Hypercholesterolemia
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2078 - 2082.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.